ASH 2024 Highlights Podcast

In this episode [13:28], Medicom’s correspondent covers 6 presentations from annual meeting of the American Society of Hematology (ASH 2024), held in San Diego, CA, USA, from December 7-10, 2024.

The topics discussed are:

1. InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?
   A treatment regimen of tafasitamab plus lenalidomide and rituximab outperformed lenalidomide plus rituximab and a placebo in patients with relapsed or refractory follicular lymphoma in a phase 3 study, representing a potential new standard of care.
2. LUNA 3: Rilzabrutinib meets primary endpoint in ITP
   In the phase 3 LUNA 3 trial, rilzabrutinib, compared with placebo, improved efficacy and quality-of-life outcomes with an accompanying favourable safety profile among heavily pre-treated adult patients with immune thrombocytopenia (ITP).
3. Full-dose or reduced-dose DOACs in high-risk VTE on extended therapy?
   In patients with venous thromboembolism who needed extended anticoagulation, a reduced dose of direct oral anticoagulants (DOACs) did not meet the non-inferiority criteria for efficacy, compared with full-dose DOACs. However, the event rates were low in both arms. On the other hand, a reduced dose of DOACs was associated with fewer bleeding events than a full dose.
4. Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?
   Autologous haematopoietic stem cell transplantation (auto-SCT) did not improve the outcomes of patients with mantle cell lymphoma who had undetectable minimal residual disease (MRD) after induction therapy, indicating that auto-SCT may be redundant in this era of highly effective induction and maintenance therapies.
5. Allo-SCT improves lives of children with sickle cell anaemia and abnormal cerebral artery velocities
   Allogeneic stem cell transplantation (allo-SCT) was more efficacious than standard-of-care in paediatric patients with sickle cell anaemia who had a history of abnormal cerebral artery velocities. Allo-SCT was associated with a reduction in hospitalisation and vaso-occlusive crises, and an improved quality-of-life after 10 years of follow-up.
6. IFM2017-03: Daratumumab therapy fruitful for frail patients with MM
   Daratumumab plus lenalidomide resulted in superior progression-free survival outcomes compared with lenalidomide plus dexamethasone in frail patients with previously untreated multiple myeloma. The safety profile of the experimental treatment regimen was favourable.

Enjoy listening!

Copyright ©2024 Medicom Medical Publishers



Posted on 18 December 202418 December 2024